登录后查看消息通知
搜索
常见问题
消息
登录
首页
/
数据集
/
Grade 3 & 4 toxicities in the safety population (CTCAE version 4.03).
Grade 3 & 4 toxicities in the safety population (CTCAE version 4.03).
收藏
Figshare
2016-09-28 更新
2026-04-29 收录
药物安全性评价
临床试验不良事件
数据链接:
https://figshare.com/articles/dataset/Grade_3_4_toxicities_in_the_safety_population_CTCAE_version_4_03_/3931524
数据链接
链接失效反馈
官方服务:
问题咨询
购买咨询
在线客服
NEW
资源简介:
Grade 3 & 4 toxicities in the safety population (CTCAE version 4.03).
应用场景:
创建时间:
2016-09-28
相关数据集
Number (%) of Subjects with Adverse Events During Days 1 to 28.
疫苗安全性监测
临床试验不良事件
Note: *Determined by the investigator to be possibly or probably related to the study vaccine.
NIAID Data Ecosystem
5
0
Incidence (per 100 PY) and adjusted HR of ATEs during 1- and 2-year follow-up periods.
药物安全性评价
临床事件风险分析
Incidence (per 100 PY) and adjusted HR of ATEs during 1- and 2-year follow-up periods.
NIAID Data Ecosystem
4
0
Patient incidence of treatment-emergent gastrointestinal bleeding events with historic control (EVOLVE).
HIV药物安全性监测
临床试验不良事件
Patient incidence of treatment-emergent gastrointestinal bleeding events with historic control (EVOLVE).
Figshare
2019-03-15 更新
1
0
Number of Grade 2–4* adverse events reported.
HIV药物安全性监测
临床试验不良事件
Number of Grade 2–4* adverse events reported.
Figshare
2015-12-02 更新
5
0
Safety assessment of ADRs with BV in all trials combined.
药物安全性评价
临床不良反应监测
Abbreviation: ADRs: adverse drug reactions; RR: relative risk; BV: bevacizumab.*Cardiac events including: left ventricular (LV) dysfunction and congestive heart failure.**Pulmonary events including: e
Figshare
2015-12-03 更新
2
0
© 2023-2026 上海数据发展科技有限责任公司 版权所有
沪ICP备17003045号-15
沪公网安备31010402336585号
热门搜索
社区交流群
科研交流群
商业服务
数据资源
寻源服务
数据采集
标注服务
数据产品
代理销售
数据领域
凭证登记
数据产品
介绍推广